Compare AbbVie Inc (ABBV) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Johnson Controls International PLC — how do they compare? AbbVie Inc trades at $253.69 (market cap $449.91B), while Johnson Controls International PLC trades at $139.45 (market cap $85.79B). The key difference: AbbVie Inc is far larger — about 5.2× Johnson Controls International PLC's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | JCI | |
|---|---|---|
Market Cap | $449.91B | $85.79B |
Sector | Health | Industrials |
52-Week High | $261.07 | $148.21 |
52-Week Low | $184.85 | $103.24 |
Enterprise Value | $513.38B | $94.62B |
Dividend Yield | 2.72% | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Johnson Controls International (JCI) trades at $140.62, down 0.1% on the day, with strong analyst support showing 62% buy ratings and a consensus price target of $153.67. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $1.19 surpassing the $1.12 estimate. The company maintains solid profitability with a 14.45% net income margin and recently announced a $0.40 dividend payable in July 2026. Technical indicators show a bullish trend with support at $139 and resistance at $145.
JCI presents a favorable investment case with earnings momentum, strong analyst conviction, and exposure to growing markets like data center cooling. Key risks include elevated valuation multiples (P/E of 43.65) and increasing debt-to-asset ratios. The stock's current price offers approximately 9% upside to consensus targets, though investors should monitor execution on revenue growth projections and competitive pressures in the building solutions sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
